Alseres Pharmaceuticals, Inc.
ALSE · OTC
12/31/2013 | 12/31/2012 | 12/31/2011 | 12/31/2010 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.02 | 0.01 | 0.00 | -0.06 |
| FCF Yield | -234.32% | -194.31% | -174.91% | -92.14% |
| EV / EBITDA | -17.34 | -5.69 | -28.93 | -3.95 |
| Quality | ||||
| ROIC | 76.81% | 45.04% | 140.10% | 82.95% |
| Gross Margin | 95.00% | 100.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 1.79 | 0.58 | – | -5.76 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | -77.11% | 61.71% | 15.71% | 63.39% |
| Safety | ||||
| Net Debt / EBITDA | -15.86 | -5.28 | -27.51 | -3.60 |
| Interest Coverage | -2.13 | -2.79 | -0.85 | -1.18 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -7,704.65 | 0.00 | 0.00 | -22,279.52 |